DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in barrett's esophagus

American Journal of Gastroenterology

Volumn 104, Issue 9, 2009, Pages 2153-2160

  Wang, Jean S ^a   Guo, Mingzhou ^b,c   Montgomery, Elizabeth A ^d   Thompson, Richard E ^b   Cosby, Hilary ^a   Hicks, Lisa ^a   Wang, Shelun ^b,e   Herman, James G ^b   Canto, Marcia I ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e 306 HOSPITAL OF PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; PROTEIN P16;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, APC; GENES, P16; HUMANS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS;

EID: 69949111978     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.300     Document Type: Article

References (50)

1. Shaheen N, Ransohoff DF. Gastroesophageal refl ux, Barrett esophagus, and esophageal cancer: clinical applications. JAMA 2002; 287: 1982-6.
2. Montgomery E, Goldblum JR, Greenson JK et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001; 32: 379-88.
3. Montgomery E, Bronner MP, Goldblum JR et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffi rmation. Hum Pathol 2001; 32: 368-78.
4. Cameron AJ, Ott BJ, Payne WS. Th e incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-9.
5. Williamson WA, Ellis FH Jr, Gibb SP et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Int Med 1991; 151: 2212-6.
6. Spechler SJ, Robbins AH, Rubins HB et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984; 87: 927-33.
7. Reid BJ, Weinstein WM. Barrett's esophagus and adenocarcinoma. Annu Rev Med 1987; 38: 477-92.
8. Licchesi JD, Westra WH, Hooker CM et al. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 2008; 14: 2570-8.
9. Licchesi JD, Westra WH, Hooker CM et al. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008; 29: 895-904.
10. Eads CA, Lord RV, Kurumboor SK et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000; 60: 5021-6.
11. Kass SU, Pruss D, Wolff e AP. How does DNA methylation repress transcription? Trends Genet 1997; 13: 444-9.
12. Bachman KE, Herman JG, Corn PG et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999; 59: 798-802.
13. Baylin S. DNA methylation and epigenetic mechanisms of carcinogenesis. Dev Biol (Basel) 2001; 106: 85-7; discussion 143-160.
14. Baylin SB, Belinsky SA, Herman JG. Aberrant methylation of gene promoters in cancer - concepts, misconcepts, and promise. J Natl Cancer Inst 2000; 92: 1460-1.
15. Corn PG, Kuerbitz SJ, van Noesel MM et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5 - CpG island methylation. Cancer Res 1999; 59: 3352-6.
16. Esteller M, Catasus L, Matias-Guiu X et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999; 155: 1767-72.
17. Esteller M, Corn PG, Baylin SB et al. A gene hypermethylation profi le of human cancer. Cancer Res 2001; 61: 3225-9.
18. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNArepair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-4.
19. Esteller M, Risques RA, Toyota M et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001; 61: 4689-92.
20. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-9.
21. Schulmann K, Sterian A, Berki A et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005; 24: 4138-48.
22. Bian YS, Osterheld MC, Fontolliet C et al. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002; 122: 1113-21.
23. Wong DJ, Barrett MT, Stoger R et al. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997; 57: 2619-22.
24. Kempster S, Phillips WA, Baindur-Hudson S et al. Methylation of exon 2 of p16 is associated with late stage oesophageal cancer. Cancer Lett 2000; 150: 57-62.
25. Klump B, Hsieh CJ, Holzmann K et al. Hypermethylation of the CDKN2/ p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 1998; 115: 1381-6.
26. Wong DJ, Paulson TG, Prevo LJ et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001; 61: 8284-9.
27. Kawakami K, Brabender J, Lord RV et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000; 92: 1805-11.
28. Levine DS, Haggitt RC, Blount PL et al. An endoscopic biopsy protocol can diff erentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105: 40-50.
29. Reid BJ, Blount PL, Feng Z et al. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95: 3089-96.
30. Schlemper RJ, Riddell RH, Kato Y et al. Th e Vienna classifi cation of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-5.
31. Herman JG, Graff JR, Myohanen S et al. Methylation-specifi c PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-6.
32. Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954-8.
33. House MG, Guo M, Iacobuzio-Donahue C et al. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003; 24: 193-8.
34. House MG, Herman JG, Guo MZ et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 2003; 238: 423-32.
35. Conio M, Filiberti R, Blanchi S et al. Risk factors for Barrett's esophagus: a case-control study. Int J Cancer 2002; 97: 225-9.
36. Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal refl ux disease: a multivariable analysis in veterans. J Clin Gastroenterol 2001; 33: 306-9.
37. Gerson LB, Edson R, Lavori PW et al. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal refl ux. Am J Gastroenterol 2001; 96: 2005-12.
38. O' Connor JB, Falk GW, Richter JE. Th e incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999; 94: 2037-42.
39. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999; 94: 3413-9.
40. Reid BJ, Levine DS, Longton G et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and fl ow cytometry identify lowand high-risk patient subsets. Am J Gastroenterol 2000; 95: 1669-76.
41. Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120: 1607-19.
42. Wang J, Cosby H, Hicks L et al. No occult cancer at esophagectomy in patients with Barrett's esophagus with high-grade dysplasia who have undergone surveillance with the Seattle biopsy protocol. Gastroenterology 2007; 132: A64.
43. Clement G, Braunschweig R, Pasquier N et al. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol 2006; 208: 100-7.
44. Reid BJ. p53 and neoplastic progression in Barrett's esophagus. Am J Gastroenterol 2001; 96: 1321-3.
45. Weston AP, Banerjee SK, Sharma P et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001; 96: 1355-62.
46. Rabinovitch PS, Longton G, Blount PL et al. Predictors of progression in Barrett's esophagus III: baseline fl ow cytometric variables. Am J Gastroenterol 2001; 96: 3071-83.
47. Tselepis C, Morris CD, Wakelin D et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidifi ed bile acid in vitro. Gut 2003; 52: 174-80.
48. Edelstein ZR, Farrow DC, Bronner MP et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007; 133: 403-11.
49. Dong LM, Kristal AR, Peters U et al. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutr Cancer 2008; 60: 39-48.
50. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76: 1116-9.